Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor ...

This performance was largely driven by the impressive growth of REZLIDHIA, the company’s mIDH1 inhibitor for relapsed/refractory acute myeloid leukemia (AML), which saw a 107% year-over-year ...

After hours: March 13 at 5:07:52 PM EDT Loading Chart for RIGL ...

This performance was largely driven by the impressive growth of REZLIDHIA, the company’s mIDH1 inhibitor for relapsed/refractory acute myeloid leukemia (AML), which saw a 107% year-over-year increase.

Revenue for the fourth quarter was $57.6 million, with product revenues from Tavalisse, Rezlidhia, and Gavreto contributing significantly. Citi analysts have raised their price target for Rigel to ...